The Therapeutic Effectiveness of the Coadministration of Weekly Risedronate and Proton Pump Inhibitor in Osteoporosis Treatment
Table 2
The background data, including age, body weight, body height, years since menopause, serum levels of calcium, phosphate and renal function indicated by creatinine, and the measured numeric values of the BMD, NTX/Cr, BAP, PTH, and the physical parameters at the baseline.